Bryostatin-1 has the potential to improve the response rate and durability of a wide range of immuno-oncology drugs and technologies. To maximize the compound’s therapeutic and commercial utility, the company plans to collaborate with academic organizations, biopharmaceutical companies and NIH to enhance efficacy of their immuno-oncology compounds. Similarly, the company expects to enter collaborations and partnerships to develop a functional cure for HIV using bryostatin analogs to activate latent HIV infected cells.